Zyme Communications
@zymecommunications.bsky.social
Specialist communications for life sciences
Pinned
A lovely way to start the year – Zyme is named #1 Marketing Agency by @businessweekly.bsky.social, with reference to the quality of our work, our global expansion, and recruitment. Congratulations to all the agencies listed in the top 10, and thank you Tony Quested and of course our brilliant team!
Today FUJIFILM Biosciences has announced a strategic alliance with CHITOSE, combining CHITOSE’s expertise in cell line development with FUJIFILM Biosciences’ advanced culture media development, to drive global innovation and biopharmaceutical manufacturing.
More: bit.ly/495M00j
More: bit.ly/495M00j
December 18, 2025 at 2:14 PM
Today FUJIFILM Biosciences has announced a strategic alliance with CHITOSE, combining CHITOSE’s expertise in cell line development with FUJIFILM Biosciences’ advanced culture media development, to drive global innovation and biopharmaceutical manufacturing.
More: bit.ly/495M00j
More: bit.ly/495M00j
Atelerix today announced a partnership with Cherry Biotech, bringing together proven non-cryogenic biosample preservation technology and advanced organoid models to support growth in the preclinical research and biotech sectors.
Read more: rb.gy/ver8ru
Read more: rb.gy/ver8ru
December 15, 2025 at 9:57 AM
Atelerix today announced a partnership with Cherry Biotech, bringing together proven non-cryogenic biosample preservation technology and advanced organoid models to support growth in the preclinical research and biotech sectors.
Read more: rb.gy/ver8ru
Read more: rb.gy/ver8ru
EpilepsyGTx has raised $33 million in Series A financing to advance its lead gene therapy programme EPY201 through Phase 1/2a clinical trials. The round included investment from XGEN Venture, the British Business Bank, and a global biopharmaceutical company: www.epilepsygtx.com/news/epileps...
December 10, 2025 at 10:20 AM
EpilepsyGTx has raised $33 million in Series A financing to advance its lead gene therapy programme EPY201 through Phase 1/2a clinical trials. The round included investment from XGEN Venture, the British Business Bank, and a global biopharmaceutical company: www.epilepsygtx.com/news/epileps...
Enterprise Therapeutics has published results of its Phase 1 study of ETD001 in the Journal of Cystic Fibrosis, demonstrating that ETD001 is well tolerated in healthy individuals at higher doses than predicted to be therapeutic.
bit.ly/44JW11K
bit.ly/44JW11K
December 9, 2025 at 11:55 AM
Enterprise Therapeutics has published results of its Phase 1 study of ETD001 in the Journal of Cystic Fibrosis, demonstrating that ETD001 is well tolerated in healthy individuals at higher doses than predicted to be therapeutic.
bit.ly/44JW11K
bit.ly/44JW11K
VALANX Biotech today announced the formation of its Board of Directors, bringing together industry leaders to support the company's strategic direction as VALANX advances from a research-stage organisation into clinical development and technology commercialisation.
Read more: bit.ly/3Y2voS9
Read more: bit.ly/3Y2voS9
December 9, 2025 at 10:41 AM
VALANX Biotech today announced the formation of its Board of Directors, bringing together industry leaders to support the company's strategic direction as VALANX advances from a research-stage organisation into clinical development and technology commercialisation.
Read more: bit.ly/3Y2voS9
Read more: bit.ly/3Y2voS9
This morning, Lab Thread announced the beta release of its flagship platform, a unified lab software designed to simplify and streamline collaboration across biological research.
Read the full press release here: bit.ly/48DZXlH
Read the full press release here: bit.ly/48DZXlH
December 8, 2025 at 9:08 AM
This morning, Lab Thread announced the beta release of its flagship platform, a unified lab software designed to simplify and streamline collaboration across biological research.
Read the full press release here: bit.ly/48DZXlH
Read the full press release here: bit.ly/48DZXlH
This morning, Atelerix announced a new partnership with Labskin, a global leader in laboratory-grown human skin models, to enable the long distance transport of Labskin's advanced in vitro skin models.
Read the full press release: bit.ly/4iG9pKc
Read the full press release: bit.ly/4iG9pKc
December 2, 2025 at 11:24 AM
This morning, Atelerix announced a new partnership with Labskin, a global leader in laboratory-grown human skin models, to enable the long distance transport of Labskin's advanced in vitro skin models.
Read the full press release: bit.ly/4iG9pKc
Read the full press release: bit.ly/4iG9pKc
Today @trimtechtx.bsky.social announced the appointment of Alison Lawton as Chair of its Board of Directors, bringing substantial expertise in operations and drug development to support TRIMTECH’s accelerated portfolio advancement and next stage of growth ➡️ shorturl.at/xXXbC
December 2, 2025 at 9:33 AM
Today @trimtechtx.bsky.social announced the appointment of Alison Lawton as Chair of its Board of Directors, bringing substantial expertise in operations and drug development to support TRIMTECH’s accelerated portfolio advancement and next stage of growth ➡️ shorturl.at/xXXbC
@sptlabtech.bsky.social has collaborated with PacBio to automate PacBio’s Kinnex full-length RNA-seq library prep on SPT’s firefly platform.
Validated at Seattle Children’s Genomics & Spatial Biology CoLab, the workflow improves reproducibility and scalability: bit.ly/4ianz63
Validated at Seattle Children’s Genomics & Spatial Biology CoLab, the workflow improves reproducibility and scalability: bit.ly/4ianz63
November 20, 2025 at 2:08 PM
@sptlabtech.bsky.social has collaborated with PacBio to automate PacBio’s Kinnex full-length RNA-seq library prep on SPT’s firefly platform.
Validated at Seattle Children’s Genomics & Spatial Biology CoLab, the workflow improves reproducibility and scalability: bit.ly/4ianz63
Validated at Seattle Children’s Genomics & Spatial Biology CoLab, the workflow improves reproducibility and scalability: bit.ly/4ianz63
Scottish Brain Sciences today announced that it has opened a new state-of-the-art clinical research centre at #ONEBioHub Aberdeen, a launchpad for start-ups and high potential life science companies looking to rapidly scale and grow.
Read more here: bit.ly/4822S7B
Read more here: bit.ly/4822S7B
November 17, 2025 at 11:05 AM
Scottish Brain Sciences today announced that it has opened a new state-of-the-art clinical research centre at #ONEBioHub Aberdeen, a launchpad for start-ups and high potential life science companies looking to rapidly scale and grow.
Read more here: bit.ly/4822S7B
Read more here: bit.ly/4822S7B
Mosaic Tx has appointed Dr Stephen Shuttleworth as CSO to lead its scientific strategy.
With over 30 years of experience, Stephen will support the Company to bring its lead products into the clinic and to build out its pipeline of precision oncology programmes: shorturl.at/aNjay
With over 30 years of experience, Stephen will support the Company to bring its lead products into the clinic and to build out its pipeline of precision oncology programmes: shorturl.at/aNjay
November 17, 2025 at 9:39 AM
Mosaic Tx has appointed Dr Stephen Shuttleworth as CSO to lead its scientific strategy.
With over 30 years of experience, Stephen will support the Company to bring its lead products into the clinic and to build out its pipeline of precision oncology programmes: shorturl.at/aNjay
With over 30 years of experience, Stephen will support the Company to bring its lead products into the clinic and to build out its pipeline of precision oncology programmes: shorturl.at/aNjay
Shift Bioscience released new research detailing an improved framework for evaluating benchmark metric calibration in virtual cell models, reinforcing the use of AI virtual cells to accelerate target identification pipelines.
Learn more: shiftbioscience.com/shift-biosci...
Learn more: shiftbioscience.com/shift-biosci...
November 11, 2025 at 10:01 AM
Shift Bioscience released new research detailing an improved framework for evaluating benchmark metric calibration in virtual cell models, reinforcing the use of AI virtual cells to accelerate target identification pipelines.
Learn more: shiftbioscience.com/shift-biosci...
Learn more: shiftbioscience.com/shift-biosci...
Today @trimtechtx.bsky.social announced the appointment of Dr Mike Hutton to its Scientific Advisory Board.
Read the full press release here: trimtechtherapeutics.com/trimtech-the...
Read the full press release here: trimtechtherapeutics.com/trimtech-the...
November 11, 2025 at 9:36 AM
Today @trimtechtx.bsky.social announced the appointment of Dr Mike Hutton to its Scientific Advisory Board.
Read the full press release here: trimtechtherapeutics.com/trimtech-the...
Read the full press release here: trimtechtherapeutics.com/trimtech-the...
@sptlabtech.bsky.social and @alitheagenomics.bsky.social have collaborated to provide an automated solution for single-cell transcriptomics, integrating the MERCURIUS FLASH-seq with SPT’s firefly platform for high-throughput, cost efficient single-cell sequencing: www.sptlabtech.com/news/spt-lab...
November 5, 2025 at 9:18 AM
@sptlabtech.bsky.social and @alitheagenomics.bsky.social have collaborated to provide an automated solution for single-cell transcriptomics, integrating the MERCURIUS FLASH-seq with SPT’s firefly platform for high-throughput, cost efficient single-cell sequencing: www.sptlabtech.com/news/spt-lab...
Today Optibrium introduced the latest release of its comprehensive molecular design platform, StarDrop 8, integrating collaboration at every stage of the discovery process enabling medicinal chemists to progress more quickly from hit to candidate.
Read more here: bit.ly/4nGfpn9
Read more here: bit.ly/4nGfpn9
November 4, 2025 at 10:38 AM
Today Optibrium introduced the latest release of its comprehensive molecular design platform, StarDrop 8, integrating collaboration at every stage of the discovery process enabling medicinal chemists to progress more quickly from hit to candidate.
Read more here: bit.ly/4nGfpn9
Read more here: bit.ly/4nGfpn9
Today Nuclera announced expanded access to its eProtein Discovery System for APAC customers through a distributor agreement with Solve Scientific in Australia and New Zealand, providing localised support and expertise to scientists in these regions.
bit.ly/3LsJYz3
bit.ly/3LsJYz3
November 3, 2025 at 12:37 PM
Today Nuclera announced expanded access to its eProtein Discovery System for APAC customers through a distributor agreement with Solve Scientific in Australia and New Zealand, providing localised support and expertise to scientists in these regions.
bit.ly/3LsJYz3
bit.ly/3LsJYz3
@proimmune.bsky.social has introduced ProVE SL Self-Loading Class I Monomers, designed to offer unprecedented flexibility, speed and MHC allele-coverage in T cell research, with over 50 alleles available.
Read more: www.proimmune.com/news
Read more: www.proimmune.com/news
October 30, 2025 at 4:12 PM
@proimmune.bsky.social has introduced ProVE SL Self-Loading Class I Monomers, designed to offer unprecedented flexibility, speed and MHC allele-coverage in T cell research, with over 50 alleles available.
Read more: www.proimmune.com/news
Read more: www.proimmune.com/news
VALANX Biotech has appointed Klaus Orlinger, PhD. as CSO.
Klaus is an experienced R&D leader with a distinguished track record in pharmaceutical product development joining VALANX from HOOKIPA Pharma, where he served as CSO, VP Research, and Head of Virology.
Read more here: rb.gy/qva8kz
Klaus is an experienced R&D leader with a distinguished track record in pharmaceutical product development joining VALANX from HOOKIPA Pharma, where he served as CSO, VP Research, and Head of Virology.
Read more here: rb.gy/qva8kz
October 30, 2025 at 9:55 AM
VALANX Biotech has appointed Klaus Orlinger, PhD. as CSO.
Klaus is an experienced R&D leader with a distinguished track record in pharmaceutical product development joining VALANX from HOOKIPA Pharma, where he served as CSO, VP Research, and Head of Virology.
Read more here: rb.gy/qva8kz
Klaus is an experienced R&D leader with a distinguished track record in pharmaceutical product development joining VALANX from HOOKIPA Pharma, where he served as CSO, VP Research, and Head of Virology.
Read more here: rb.gy/qva8kz
Today Qureight announced that its Vascul8™ model for pulmonary vascular disorders has been validated in a peer reviewed study, offering the potential to improve treatment options and patient outcomes following surgery.
Read the full press release here: bit.ly/48OeEo5
Read the full press release here: bit.ly/48OeEo5
October 27, 2025 at 9:29 AM
Today Qureight announced that its Vascul8™ model for pulmonary vascular disorders has been validated in a peer reviewed study, offering the potential to improve treatment options and patient outcomes following surgery.
Read the full press release here: bit.ly/48OeEo5
Read the full press release here: bit.ly/48OeEo5
OMED Health, part of @owlstonemedical.bsky.social, has partnered with Aviva to deliver a pilot study, providing 75 Aviva employees with OMED Health Plans.
The collaboration will evaluate the impact of the OMED solution on the digestive health of participants: www.owlstonemedical.com/about/news/2...
The collaboration will evaluate the impact of the OMED solution on the digestive health of participants: www.owlstonemedical.com/about/news/2...
October 23, 2025 at 8:26 AM
OMED Health, part of @owlstonemedical.bsky.social, has partnered with Aviva to deliver a pilot study, providing 75 Aviva employees with OMED Health Plans.
The collaboration will evaluate the impact of the OMED solution on the digestive health of participants: www.owlstonemedical.com/about/news/2...
The collaboration will evaluate the impact of the OMED solution on the digestive health of participants: www.owlstonemedical.com/about/news/2...
Biodesix has expanded its partnership agreement with @biorad24.bsky.social to develop in vitro diagnostic assays for highly sensitive detection of genomic markers focused on oncology applications, utilizing Bio-Rad’s ddPCR™ technology & QX600 platform.
More here: rb.gy/5wbz3q
More here: rb.gy/5wbz3q
October 22, 2025 at 12:17 PM
Biodesix has expanded its partnership agreement with @biorad24.bsky.social to develop in vitro diagnostic assays for highly sensitive detection of genomic markers focused on oncology applications, utilizing Bio-Rad’s ddPCR™ technology & QX600 platform.
More here: rb.gy/5wbz3q
More here: rb.gy/5wbz3q
@proimmune.bsky.social has expanded into new global headquarters at Oasis Park, Oxford, supporting the continued development of ProImmune’s REVEAL Immunogenicity System and Ankyron target binding technologies.
Read more: proimmune.com/news
Read more: proimmune.com/news
October 22, 2025 at 8:11 AM
@proimmune.bsky.social has expanded into new global headquarters at Oasis Park, Oxford, supporting the continued development of ProImmune’s REVEAL Immunogenicity System and Ankyron target binding technologies.
Read more: proimmune.com/news
Read more: proimmune.com/news
giles AI has introduced giles, its specialised research agent designed to support healthcare, clinical, and medical research by optimising research intelligence for scientific text comprehension, enabling extraction and summarisation of academic papers: giles.app/press-releas...
October 22, 2025 at 8:02 AM
giles AI has introduced giles, its specialised research agent designed to support healthcare, clinical, and medical research by optimising research intelligence for scientific text comprehension, enabling extraction and summarisation of academic papers: giles.app/press-releas...
Bio-Rad Laboratories today announced that MicroVal, the international certification organization, has approved the iQ-Check Enterobacteriaceae Kit for real time detection of Enterobacteriaceae in infant formula, infant cereal, and related ingredients: www.bio-rad.com/en-uk/life-s...
October 21, 2025 at 9:09 AM
Bio-Rad Laboratories today announced that MicroVal, the international certification organization, has approved the iQ-Check Enterobacteriaceae Kit for real time detection of Enterobacteriaceae in infant formula, infant cereal, and related ingredients: www.bio-rad.com/en-uk/life-s...
Today Enamine announced that it was a key synthetic chemistry contributor to a first-of-its-kind, open-science approach that led to the development of ASAP-0017445, a promising broad-spectrum coronavirus antiviral pre-clinical candidate.
Read more: enamine.net/news-press-r...
Read more: enamine.net/news-press-r...
October 21, 2025 at 8:13 AM
Today Enamine announced that it was a key synthetic chemistry contributor to a first-of-its-kind, open-science approach that led to the development of ASAP-0017445, a promising broad-spectrum coronavirus antiviral pre-clinical candidate.
Read more: enamine.net/news-press-r...
Read more: enamine.net/news-press-r...